Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases

Overview

Observational study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases

Full Title of Study: “Clinical and Therapeutic Evaluation of Meloxicam in Mexican Patients With Rheumatic Diseases”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2007

Interventions

  • Drug: Meloxicam

Arms, Groups and Cohorts

  • Meloxicam

Clinical Trial Outcome Measures

Primary Measures

  • Intensity of symptoms at rest evaluated with a 4-point scale
    • Time Frame: 30 and 90 days
  • Intensity of symptoms during movement evaluated with a 4-point scale
    • Time Frame: 30 and 90 days
  • Medical global evaluation on a 4-point scale
    • Time Frame: 30 and 90 days

Participating in This Clinical Trial

Inclusion Criteria

  • Age of 12 or older and rheumatologic disease

Exclusion Criteria

  • Hypersensitivity to meloxicam
  • Hypersensitivity to other Non-steroidal anti-inflammatory drugs (NSAIDS)
  • History of asthma, angioedema or urticaria secondary to NSAIDS
  • Pregnancy or lactation
  • Recent or current history of peptic ulcer disease, severe renal failure and severe hepatic failure

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.